Floatz logo

BICALUTAMIDE

Prostate Adenocarcinoma

OHSU Knight Cancer InstituteSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

88 Active assets in the Prostate Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Docetaxel
Instituto do Cancer do Estado de São Paulo
Phase 3BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
Degarelix
Canadian Cancer Trials Group
Phase 3BB
NILUTAMIDE
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

BICALUTAMIDE is also rated in:

triple-negative breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 4
67 / 100
View asset →
metastatic prostate carcinomaActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →